CannBioRx Cost Of Revenue vs Other Operating Expenses Analysis

ATNFW Stock

USD 0.01 0 22.22%

CannBioRx Life financial indicator trend analysis is way more than just evaluating CannBioRx Life Sciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CannBioRx Life Sciences is a good investment. Please check the relationship between CannBioRx Life Cost Of Revenue and its Other Operating Expenses accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CannBioRx Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

Cost Of Revenue vs Other Operating Expenses

Cost Of Revenue vs Other Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CannBioRx Life Sciences Cost Of Revenue account and Other Operating Expenses. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between CannBioRx Life's Cost Of Revenue and Other Operating Expenses is 0.58. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of CannBioRx Life Sciences, assuming nothing else is changed. The correlation between historical values of CannBioRx Life's Cost Of Revenue and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of CannBioRx Life Sciences are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Cost Of Revenue i.e., CannBioRx Life's Cost Of Revenue and Other Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.58

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on CannBioRx Life Sciences income statement and represents the costs associated with goods and services CannBioRx Life provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of CannBioRx Life Sciences. It is also known as CannBioRx Life overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most indicators from CannBioRx Life's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CannBioRx Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CannBioRx Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

Selling General Administrative is likely to drop to about 7.6 M in 2024. Tax Provision is likely to climb to about (3.1 M) in 2024

	2021	2022	2023	2024 (projected)
Research Development	3.9M	2.4M	2.8M	2.7M
Depreciation And Amortization	116.3K	109.0K	105.7K	101.1K

Research Development Depreciation And Amortization

CannBioRx Life fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Cash And Short Term Investments	Capital Surpluse	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Current Liab	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity	Short Long Term Debt Total	Accounts Payable	Net Receivables	Good Will	Common Stock Total Equity	Inventory	Other Current Assets
Total Assets		0.25	0.43	0.09	0.87	0.69	0.44	0.13	0.88	0.85	0.28	0.03	0.08	0.05	-0.08	0.17	-0.08	0.22	0.03	0.13	0.1	0.22	0.24	0.22	0.34	0.07
Total Current Liabilities	0.25		0.84	-0.52	-0.21	0.57	0.97	0.72	0.52	-0.25	0.89	-0.17	0.62	-0.61	-0.82	0.64	-0.8	-0.2	0.75	-0.3	0.08	0.86	-0.11	-0.14	0.68	0.75
Total Stockholder Equity	0.43	0.84		-0.24	-0.07	0.53	0.91	0.55	0.63	-0.1	0.78	-0.05	0.47	-0.37	-0.64	0.41	-0.64	0.14	0.55	-0.06	0.03	0.66	0.18	0.23	0.67	0.48
Retained Earnings	0.09	-0.52	-0.24		0.25	-0.63	-0.42	-0.72	-0.18	0.29	-0.37	0.39	-0.67	0.98	0.89	-0.1	0.89	0.89	-0.94	0.91	0.45	-0.42	0.89	0.7	0.22	-0.8
Cash And Short Term Investments	0.87	-0.21	-0.07	0.25		0.46	-0.04	-0.15	0.6	1.0	-0.13	0.03	-0.16	0.27	0.28	-0.11	0.29	0.19	-0.28	0.18	0.04	-0.15	0.17	0.14	-0.02	-0.2
Capital Surpluse	0.69	0.57	0.53	-0.63	0.46		0.65	0.56	0.83	0.42	0.43	-0.15	0.46	-0.68	-0.71	0.24	-0.71	-0.46	0.71	-0.51	-0.17	0.43	-0.44	-0.3	0.08	0.56
Total Liab	0.44	0.97	0.91	-0.42	-0.04	0.65		0.69	0.65	-0.08	0.88	-0.16	0.59	-0.52	-0.76	0.64	-0.74	-0.06	0.67	-0.22	0.11	0.85	0.0	0.04	0.72	0.68
Total Current Assets	0.13	0.72	0.55	-0.72	-0.15	0.56	0.69		0.22	-0.22	0.8	-0.77	0.99	-0.71	-0.81	0.15	-0.76	-0.37	0.78	-0.74	-0.52	0.78	-0.47	-0.18	0.29	0.92
Short Term Debt	0.88	0.52	0.63	-0.18	0.6	0.83	0.65	0.22		0.59	0.34	0.22	0.11	-0.29	-0.42	0.43	-0.43	-0.02	0.37	0.03	0.25	0.38	0.04	0.01	0.33	0.18
Common Stock	0.85	-0.25	-0.1	0.29	1.0	0.42	-0.08	-0.22	0.59		-0.18	0.08	-0.22	0.31	0.32	-0.11	0.32	0.2	-0.32	0.22	0.07	-0.2	0.19	0.14	-0.04	-0.25
Other Current Liab	0.28	0.89	0.78	-0.37	-0.13	0.43	0.88	0.8	0.34	-0.18		-0.47	0.75	-0.4	-0.63	0.4	-0.59	-0.02	0.56	-0.31	-0.18	0.82	0.05	0.05	0.78	0.81
Net Debt	0.03	-0.17	-0.05	0.39	0.03	-0.15	-0.16	-0.77	0.22	0.08	-0.47		-0.85	0.28	0.29	0.29	0.22	0.17	-0.3	0.65	0.73	-0.43	0.36	0.02	-0.04	-0.66
Cash	0.08	0.62	0.47	-0.67	-0.16	0.46	0.59	0.99	0.11	-0.22	0.75	-0.85		-0.64	-0.72	0.05	-0.67	-0.32	0.7	-0.73	-0.58	0.75	-0.46	-0.15	0.24	0.88
Non Current Assets Total	0.05	-0.61	-0.37	0.98	0.27	-0.68	-0.52	-0.71	-0.29	0.31	-0.4	0.28	-0.64		0.94	-0.19	0.95	0.83	-0.98	0.84	0.35	-0.47	0.83	0.64	0.15	-0.76
Non Currrent Assets Other	-0.08	-0.82	-0.64	0.89	0.28	-0.71	-0.76	-0.81	-0.42	0.32	-0.63	0.29	-0.72	0.94		-0.36	0.99	0.62	-0.99	0.71	0.24	-0.68	0.61	0.43	-0.15	-0.82
Common Stock Shares Outstanding	0.17	0.64	0.41	-0.1	-0.11	0.24	0.64	0.15	0.43	-0.11	0.4	0.29	0.05	-0.19	-0.36		-0.34	0.08	0.26	0.21	0.76	0.66	0.13	0.08	0.61	0.17
Short Term Investments	-0.08	-0.8	-0.64	0.89	0.29	-0.71	-0.74	-0.76	-0.43	0.32	-0.59	0.22	-0.67	0.95	0.99	-0.34		0.64	-0.99	0.69	0.23	-0.62	0.61	0.46	-0.12	-0.78
Non Current Liabilities Total	0.22	-0.2	0.14	0.89	0.19	-0.46	-0.06	-0.37	-0.02	0.2	-0.02	0.17	-0.32	0.83	0.62	0.08	0.64		-0.72	0.82	0.41	-0.02	0.91	0.91	0.49	-0.56
Other Stockholder Equity	0.03	0.75	0.55	-0.94	-0.28	0.71	0.67	0.78	0.37	-0.32	0.56	-0.3	0.7	-0.98	-0.99	0.26	-0.99	-0.72		-0.78	-0.32	0.58	-0.7	-0.54	0.03	0.82
Short Long Term Debt Total	0.13	-0.3	-0.06	0.91	0.18	-0.51	-0.22	-0.74	0.03	0.22	-0.31	0.65	-0.73	0.84	0.71	0.21	0.69	0.82	-0.78		0.72	-0.27	0.88	0.58	0.33	-0.79
Accounts Payable	0.1	0.08	0.03	0.45	0.04	-0.17	0.11	-0.52	0.25	0.07	-0.18	0.73	-0.58	0.35	0.24	0.76	0.23	0.41	-0.32	0.72		0.1	0.47	0.28	0.35	-0.5
Net Receivables	0.22	0.86	0.66	-0.42	-0.15	0.43	0.85	0.78	0.38	-0.2	0.82	-0.43	0.75	-0.47	-0.68	0.66	-0.62	-0.02	0.58	-0.27	0.1		-0.11	0.06	0.64	0.68
Good Will	0.24	-0.11	0.18	0.89	0.17	-0.44	0.0	-0.47	0.04	0.19	0.05	0.36	-0.46	0.83	0.61	0.13	0.61	0.91	-0.7	0.88	0.47	-0.11		0.74	0.61	-0.51
Common Stock Total Equity	0.22	-0.14	0.23	0.7	0.14	-0.3	0.04	-0.18	0.01	0.14	0.05	0.02	-0.15	0.64	0.43	0.08	0.46	0.91	-0.54	0.58	0.28	0.06	0.74		0.43	-0.42
Inventory	0.34	0.68	0.67	0.22	-0.02	0.08	0.72	0.29	0.33	-0.04	0.78	-0.04	0.24	0.15	-0.15	0.61	-0.12	0.49	0.03	0.33	0.35	0.64	0.61	0.43		0.3
Other Current Assets	0.07	0.75	0.48	-0.8	-0.2	0.56	0.68	0.92	0.18	-0.25	0.81	-0.66	0.88	-0.76	-0.82	0.17	-0.78	-0.56	0.82	-0.79	-0.5	0.68	-0.51	-0.42	0.3

Click cells to compare fundamentals

CannBioRx Life Account Relationship Matchups

CannBioRx Life fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	51.9M	55.5M	62.7M	19.7M	5.3M	5.0M
Total Current Liabilities	9.6M	21.4M	19.7M	5.7M	5.1M	8.6M
Total Stockholder Equity	38.6M	30.3M	39.3M	11.3M	(127.7K)	(121.3K)
Retained Earnings	(37.5M)	(48.4M)	(68.7M)	(107.4M)	(127.3M)	(121.0M)
Cash And Short Term Investments	83.4K	2.1M	8.2M	7.0M	2.0M	1.9M
Total Liab	13.3M	25.2M	23.4M	8.3M	5.4M	5.1M
Total Current Assets	748.3K	4.0M	11.2M	8.9M	3.6M	4.0M
Common Stock	1.4K	2.6K	3.4K	375.0	54.0	51.3
Other Current Liab	2.0M	9.2M	17.2M	2.5M	1.9M	1.8M
Net Debt	3.4M	1.7M	(6.3M)	(5.6M)	(921.7K)	(967.8K)
Cash	83.4K	2.1M	8.2M	7.0M	2.0M	3.2M
Non Current Assets Total	51.1M	51.5M	51.5M	10.7M	1.6M	1.5M
Common Stock Shares Outstanding	29.0K	26.2M	82.5K	100.0K	379.1K	360.1K
Liabilities And Stockholders Equity	51.9M	55.5M	62.7M	19.7M	5.3M	5.0M
Non Current Liabilities Total	3.7M	3.8M	3.7M	2.6M	324.6K	308.4K
Other Stockholder Equity	75.9M	78.0M	107.2M	121.6M	130.1M	136.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for CannBioRx Stock Analysis

When running CannBioRx Life's price analysis, check to measure CannBioRx Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CannBioRx Life is operating at the current time. Most of CannBioRx Life's value examination focuses on studying past and present price action to predict the probability of CannBioRx Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CannBioRx Life's price. Additionally, you may evaluate how the addition of CannBioRx Life to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CannBioRx Cost Of Revenue vs Other Operating Expenses Analysis

Cost Of Revenue vs Other Operating Expenses

Cost Of Revenue vs Other Operating Expenses Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Other Operating Expenses

CannBioRx Life fundamental ratios Correlations

CannBioRx Life Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CannBioRx Life fundamental ratios Accounts

Also Currently Popular

Additional Tools for CannBioRx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Cash And Short Term Investments
Cash	+ 0.99	Total Current Assets
Short Term Investments	+ 0.99	Non Currrent Assets Other
Non Current Assets Total	+ 0.98	Retained Earnings
Total Liab	+ 0.97	Total Current Liabilities
Short Term Investments	+ 0.95	Non Current Assets Total

Other Stockholder Equity	- 0.99	Short Term Investments
Other Stockholder Equity	- 0.99	Non Currrent Assets Other
Other Stockholder Equity	- 0.98	Non Current Assets Total
Other Stockholder Equity	- 0.94	Retained Earnings
Cash	- 0.85	Net Debt
Other Current Assets	- 0.82	Non Currrent Assets Other